
|Articles|November 11, 2007
Accommodating lens model continues trend of improved outcomes throughout implant evolution
A fourth-generation version of an accommodating IOL (HD-100 crystalens, eyeonics) provides excellent uncorrected visual acuity (UCVA) at all distances without degrading contrast acuity, according to the results of an FDA multicenter clinical trial.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Navigating antithrombotic therapy in wet AMD
2
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
3
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
4
FLORetina 2025: Multimodal deep learning for CKD diagnosis using retinal images and urine dipstick data
5













































